ABBV-637 is an EGFR-targeting ADC that consists of a BCL-XL inhibitor payload and has undergone phase I clinical trials in combination with osimertinib in EGFR-mutant NSCLC (NCT04721015). Here, EGFR is linked to non-small cell lung carcinoma.